A Novel Therapeutic Approach for Primary and Metastatic Prostate Cancer

原发性和转移性前列腺癌的新治疗方法

基本信息

批准号：
8815090
负责人：
Khalil Ahmed
金额：
$ 29.23万
依托单位：
UNIVERSITY OF MINNESOTA
依托单位国家：
美国
项目类别：
财政年份：
2011
资助国家：
美国
起止时间：
2011-03-04 至 2017-02-28
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8815090
关键词：
Abbreviations Ablation Acute Address Advanced Malignant Neoplasm Androgen Receptor Androgens Apoptosis Apoptotic Biodistribution Cancer Etiology Castration Catalytic Domain Cell Death Cell Death Induction Cell Proliferation Cell physiology Cells Cessation of life Characteristics Data Disease Disseminated Malignant Neoplasm Distant Metastasis Dose Down-Regulation Drug Delivery Systems Drug Kinetics Evaluation Future Goals Health Human Induction of Apoptosis Interruption Investigation Lead Longitudinal Studies Malignant Neoplasms Malignant neoplasm of prostate Mediating Metastatic Prostate Cancer Modeling Molecular Mus Names Nature Normal Cell Normal tissue morphology Nucleic Acids Oligonucleotides Organ Outcome Phenotype Prostate Prostate Cancer therapy Prostate-Specific Antigen Prostatic Public Health Publishing Research Resistance Signal Transduction Specificity System Therapeutic Therapeutic Agents Toxic effect Translations Work Xenograft Model Xenograft procedure acronyms base bone cancer cell cancer therapy casein kinase II castration resistant prostate cancer cell growth design design and construction in vivo innovation lymph nodes men mortality mouse model nanocapsule nanoencapsulated nanoscale neoplastic cell novel novel therapeutic intervention phosphorothioate preclinical study promoter prostate cancer cell prostate cancer model red fluorescent protein research study response success targeted cancer therapy targeted treatment therapeutic target tumor uptake

项目摘要

DESCRIPTION (provided by applicant): The primary goal of this project is to undertake preclinical studies relating to targeting of protein kinase CK2 (formerly casein kinase 2 or II) for prostate cancer therapy so that an eradication of cancer is achieved. CK2 has emerged as a "master regulator" of cell function with a profound ability to determine cell fate. CK2 is upregulated in all cancers that have been examined. Since deregulation of cell proliferation and death are hallmarks of the cancer cell phenotype, the importance of CK2 in cancer cells is underscored by the fact that CK2 is not only a promoter of cell growth and proliferation but also a potent suppressor of apoptosis. Our studies on CK2 function in prostate cell pathobiology have demonstrated that downregulation of CK2 results in potent induction of apoptosis in vivo. Building on our original proposal to target CK2 signal for prostate cancer therapy, we have developed strategies to achieve molecular downregulation of CK2 by using antisense ODN directed towards both catalytic subunits, CK2a and CK2a', called bispecific antisense CK2 or bs-As-CK2. Further, we have also devised a novel tenfibgen nanocapsule which is less than 50 nm size (sub-50 nm tenfibgen nanocapsule or s50 TBG nanocapsule) that delivers its bs-As-CK2 cargo specifically to the tumor cells overcoming the important issue of non-specific drug delivery. Thus, our central hypothesis is that molecular downregulation of the catalytic CK2a and CK2a' subunits employing bs-As-CK2 in a nanocapsule delivery vehicle for tumor cell-specific targeting will lead to induction of extensive cell death in vivo resulting in not just disease stabilization but rather eradication of primary and metastatic prostatic tumors. The proposed strategies have the strong potential of success because (a) downregulation of CK2 should impact both the proliferative and apoptotic activity in prostate cancer cells, and (b) loss of CK2 cannot be replaced by another signal in the cell. The proposed experiments in mouse models evaluate dose response in short and long term studies, and incorporate biodistribution and pharmacokinetic aspects of the tumor targeting agent. These preclinical studies are essential for future translation of this novel therapeutic approach for both primary and metastatic prostate cancer.

描述（由申请人提供）：该项目的主要目标是进行有关靶向蛋白激酶CK2（以前是酪蛋白激酶2或II）的临床前研究，以实现前列腺癌疗法，以便实现癌症的消除。 CK2已成为细胞功能的“主要调节剂”，具有确定细胞命运的深刻能力。在所有已检查的癌症中，CK2都上调。由于对细胞增殖和死亡的放松管制是癌细胞表型的标志，因此CK2不仅是细胞生长和增殖的启动子，而且是凋亡的有效抑制剂，CK2在癌细胞中的重要性强调了。我们对前列腺病理生物学中CK2功能的研究表明，CK2的下调导致体内凋亡的有效诱导。在我们针对前列腺癌疗法的最初提议的基础上，我们采用了针对催化亚基，CK2A和CK2A'的反义ODN来实现CK2分子下调的策略，称为双特异性反义CK2或BS-AS-AS-CK2。此外，我们还设计了一种新型的Tenfibgen纳米胶囊，该纳米胶囊小于50 nm的大小（低于50 nm的Tenfibgen纳米胶囊或S50 TBG纳米胶囊），该纳米胶囊将其BS-AS-CK2货物运送到特定于肿瘤细胞，以克服非特异性药物递送的重要问题。因此，我们的核心假设是，在纳米胶囊中使用BS-AS-CK2的催化CK2A和CK2A的亚基的分子下调将导致体内诱导巨大的细胞死亡，这不仅会导致疾病稳定性，而不仅会导致疾病稳定性，而且还会导致原始和转化的原发性检测。提出的策略具有成功的强大潜力，因为（a）CK2的下调应影响前列腺癌细胞中的增殖和凋亡活性，并且（b）CK2的丧失不能被细胞中的另一个信号所取代。小鼠模型中提出的实验评估了短期和长期研究中的剂量反应，并结合了肿瘤靶向剂的生物分布和药代动力学方面。这些临床前研究对于对原发性和转移性前列腺癌的这种新型治疗方法的未来翻译至关重要。

项目成果

期刊论文数量（6）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Examination of CK2α and NF-κB p65 expression in human benign prostatic hyperplasia and prostate cancer tissues.

DOI：
10.1007/s11010-016-2765-3
发表时间：
2016-09
期刊：
Molecular and cellular biochemistry
影响因子：
4.3
作者：
Qaiser F;Trembley JH;Sadiq S;Muhammad I;Younis R;Hashmi SN;Murtaza B;Rector TS;Naveed AK;Ahmed K
通讯作者：
Ahmed K

Protein kinase CK2 - diverse roles in cancer cell biology and therapeutic promise.